SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer

About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636....

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 8; p. 2271
Main Authors Tsoi, Ho, Fung, Nicholas Nok-Ching, Man, Ellen P. S., Leung, Man-Hong, You, Chan-Ping, Chan, Wing-Lok, Chan, Sum-Yin, Khoo, Ui-Soon
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 13.04.2023
MDPI
Subjects
Alternative splicing
Breast cancer
Cancer therapies
Cell cycle
Dosage and administration
Drug resistance
Drug therapy
Endocrine therapy
Estrogen receptors
Gene expression
Genetic aspects
Genetic regulation
Health aspects
Kinases
Metastases
Metastasis
mRNA
Phosphorylation
Plasmids
Proteins
Tamoxifen
Hong Kong, China
St Louis Missouri
United States > US
novel target
breast cancer
tamoxifen resistance
SRSF5
BQ323636.1
SRPK1
Online AccessGet full text

Cover

Abstract About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.
AbstractList Overexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11. SRSF5 is found to be involved in regulating the splicing of NCOR2. A low expression of SRSF5 enhances the chance of excluding exon 11 from mRNA, leading to the production of mRNA translating for BQ. Therefore, a low expression of SRSF5 can enhance BQ expression and, thus, tamoxifen resistance. SRPK1 can alter the activity of SRSF5 for BQ expression. Inhibition of SRPK1 can reduce TAM resistance by suppressing BQ expression in ER +ve breast cancer. Therefore, targeting the upstream pathway of BQ will be a possible strategy for reversing TAM resistance. About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.
Overexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11. SRSF5 is found to be involved in regulating the splicing of NCOR2. A low expression of SRSF5 enhances the chance of excluding exon 11 from mRNA, leading to the production of mRNA translating for BQ. Therefore, a low expression of SRSF5 can enhance BQ expression and, thus, tamoxifen resistance. SRPK1 can alter the activity of SRSF5 for BQ expression. Inhibition of SRPK1 can reduce TAM resistance by suppressing BQ expression in ER +ve breast cancer. Therefore, targeting the upstream pathway of BQ will be a possible strategy for reversing TAM resistance.
Simple SummaryOverexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11. SRSF5 is found to be involved in regulating the splicing of NCOR2. A low expression of SRSF5 enhances the chance of excluding exon 11 from mRNA, leading to the production of mRNA translating for BQ. Therefore, a low expression of SRSF5 can enhance BQ expression and, thus, tamoxifen resistance. SRPK1 can alter the activity of SRSF5 for BQ expression. Inhibition of SRPK1 can reduce TAM resistance by suppressing BQ expression in ER +ve breast cancer. Therefore, targeting the upstream pathway of BQ will be a possible strategy for reversing TAM resistance.AbstractAbout 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.
About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.
About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer TAM resistance. BQ is an alternative splice variant of NCOR2. The inclusion of exon 11 generates mRNA for NCOR2, while the exclusion of exon 11 produces mRNA for BQ. The expression of SRSF5 is low in TAM-resistant breast cancer cells. Modulation of SRSF5 can affect the alternative splicing of NCOR2 to produce BQ. In vitro and in vivo studies confirmed that the knockdown of SRSF5 enhanced BQ expression, and conferred TAM resistance; in contrast, SRSF5 overexpression reduced BQ expression and, thus, reversed TAM resistance. Clinical investigation using a tissue microarray confirmed the inverse correlation of SRSF5 and BQ. Low SRSF5 expression was associated with TAM resistance, local recurrence and metastasis. Survival analyses showed that low SRSF5 expression was associated with poorer prognosis. We showed that SRPK1 can interact with SRSF5 to phosphorylate it. Inhibition of SRPK1 by a small inhibitor, SRPKIN-1, suppressed the phosphorylation of SRSF5. This enhanced the proportion of SRSF5 interacting with exon 11 of NCOR2, reducing the production of BQ mRNA. As expected, SRPKIN-1 reduced TAM resistance. Our study confirms that SRSF5 is essential for BQ expression. Modulating the activity of SRSF5 in ER +ve breast cancer will be a potential approach to combating TAM resistance.
Audience Academic
Author Chan, Sum-Yin
Tsoi, Ho
You, Chan-Ping
Leung, Man-Hong
Man, Ellen P. S.
Fung, Nicholas Nok-Ching
Khoo, Ui-Soon
Chan, Wing-Lok
AuthorAffiliation 3 Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China; ann_chan81@hotmail.com
2 Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; winglok@hku.hk
1 Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; tsoiho@hku.hk (H.T.); nickf821@connect.hku.hk (N.N.-C.F.); ellenman@hku.hk (E.P.S.M.); george09@connect.hku.hk (M.-H.L.); u3006037@connect.hku.hk (C.-P.Y.)
AuthorAffiliation_xml – name: 2 Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; winglok@hku.hk
– name: 1 Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; tsoiho@hku.hk (H.T.); nickf821@connect.hku.hk (N.N.-C.F.); ellenman@hku.hk (E.P.S.M.); george09@connect.hku.hk (M.-H.L.); u3006037@connect.hku.hk (C.-P.Y.)
– name: 3 Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China; ann_chan81@hotmail.com
Author_xml – sequence: 1
  givenname: Ho
  orcidid: 0000-0003-2037-9575
  surname: Tsoi
  fullname: Tsoi, Ho
– sequence: 2
  givenname: Nicholas Nok-Ching
  surname: Fung
  fullname: Fung, Nicholas Nok-Ching
– sequence: 3
  givenname: Ellen P. S.
  surname: Man
  fullname: Man, Ellen P. S.
– sequence: 4
  givenname: Man-Hong
  surname: Leung
  fullname: Leung, Man-Hong
– sequence: 5
  givenname: Chan-Ping
  surname: You
  fullname: You, Chan-Ping
– sequence: 6
  givenname: Wing-Lok
  orcidid: 0000-0001-9793-9273
  surname: Chan
  fullname: Chan, Wing-Lok
– sequence: 7
  givenname: Sum-Yin
  surname: Chan
  fullname: Chan, Sum-Yin
– sequence: 8
  givenname: Ui-Soon
  orcidid: 0000-0003-2200-7505
  surname: Khoo
  fullname: Khoo, Ui-Soon
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37190199$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1vFCEYxiemxtbaszdD4sXLbGGY4eNk2s1WTWrU7d4Jy7xs2czCCkxT_3vZfmi7UThA4Pc8vE9eXlcHPnioqrcETyiV-NRobyAm0mHRNJy8qI4azJuaMdkePNkfVicprXEZlBLO-KvqkHIiMZHyqFpfza8uOjSH1TjoDAnla0Cz222ElFzwKFh0_oM2lFE2ISgH9DX0dyRa6E24dRZ8ESeX8q4Y5DyazevvIbnsbgCdR9Apo-ldoW-ql1YPCU4e1uNqcTFbTD_Xl98-fZmeXdamFTLXLVDWWrmUpViLO7CcaMMxsN42zVKYxmDbalgKjqXpSyDaWgNU9IILgTt6XH28t92Oyw30BnyOelDb6DY6_lJBO_X8xrtrtQo3imBCGWtpcfjw4BDDzxFSVhuXDAyD9hDGpBpB2q7hrSQFfb-HrsMYfYlXKMw6zASXf6mVHkA5b0N52OxM1RlvOcVCClyoyT-oMnvYOFNab105fyZ49zTpn4iP3S1Adw-YGFKKYJVxWefS1-LshpJY7T6S2vtIRXe6p3u0_p_iN5SmyQ4
CitedBy_id crossref_primary_10_1186_s12885_024_12750_4
Cites_doi 10.1111/febs.12797
10.1074/jbc.M314298200
10.1038/s41467-020-19242-6
10.7554/eLife.11752
10.3389/fphar.2020.592912
10.1038/nsmb1209
10.1158/0008-5472.CAN-12-2241
10.1111/febs.15626
10.1038/nsmb.2040
10.1038/s41467-021-23663-2
10.3389/fphar.2021.628690
10.1016/j.ebiom.2020.103047
10.1016/j.molcel.2016.05.034
10.1016/j.tig.2020.10.008
10.4161/epi.27111
10.1038/s41467-018-03951-0
10.1186/gb-2009-10-10-242
10.1186/s13045-021-01072-8
10.1002/ctm2.554
10.1073/pnas.1620993114
10.1172/JCI74440
10.3389/fphar.2020.550469
10.1158/1078-0432.CCR-17-2259
10.1016/S0140-6736(11)60993-8
10.3390/life12010093
10.1038/s42003-020-0983-4
10.3389/fcell.2020.00474
10.3390/ijms19010075
10.1261/rna.068619.118
10.1038/s41388-017-0027-9
10.1002/emmm.201303411
10.2174/1568009617666170808110820
10.1038/s41467-021-24198-2
10.1016/j.chembiol.2018.01.013
10.1093/nar/gkaa1074
10.1186/s12943-017-0727-3
10.1016/j.cell.2016.01.029
10.1002/1873-3468.13119
10.3390/cancers13153688
10.1158/0008-5472.CAN-16-1919
10.1038/s41467-018-04815-3
10.1038/s41389-020-00263-1
10.1016/j.breast.2022.01.012
10.1038/nature07509
10.1038/s41593-018-0265-3
10.1016/j.cell.2019.01.021
10.18632/oncotarget.27215
10.1186/s12885-016-2490-z
10.1093/carcin/bgs347
10.1073/pnas.1510176112
10.1186/s13578-021-00581-w
10.1158/2159-8290.CD-13-0253
10.3390/cancers13071511
10.3390/cells9010019
10.3390/cancers12030533
10.1038/ng.259
10.1016/j.mce.2010.10.010
10.1038/s41392-021-00486-7
10.1158/0008-5472.CAN-17-1327
10.1677/erc.1.00776
10.1016/j.bbamcr.2018.05.017
10.3390/ijms232012290
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
NPM
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers15082271
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central (New)
Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Biological Science Collection
ProQuest research library
Biological Science Database
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC10136643
A747308980
37190199
10_3390_cancers15082271
Genre Journal Article
GeographicLocations Hong Kong, China
St Louis Missouri
United States--US
GeographicLocations_xml – name: Hong Kong, China
– name: St Louis Missouri
– name: United States--US
GrantInformation_xml – fundername: General Research Fund
  grantid: 17113020
– fundername: Health and Medical Research Fund
  grantid: 07182026
– fundername: Health and Medical Research Fund
  grantid: 07182046
– fundername: General Research Fund (GRF)
  grantid: 17113020
– fundername: Health and Medical Research Fund
  grantid: 07182026; 07182046
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
3V.
GROUPED_DOAJ
NPM
PMFND
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c489t-4e364f9b9317f05ef71ac70e6df22b8c2c0f4aeb8709cd17634fce38d8788053
IEDL.DBID M48
ISSN 2072-6694
IngestDate Thu Aug 21 18:38:02 EDT 2025
Fri Jul 11 09:22:21 EDT 2025
Fri Jul 25 11:56:08 EDT 2025
Tue Jun 17 21:59:38 EDT 2025
Tue Jun 10 21:01:08 EDT 2025
Thu Jan 02 22:51:08 EST 2025
Tue Jul 01 01:21:19 EDT 2025
Thu Apr 24 23:00:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords novel target
breast cancer
tamoxifen resistance
SRSF5
BQ323636.1
SRPK1
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c489t-4e364f9b9317f05ef71ac70e6df22b8c2c0f4aeb8709cd17634fce38d8788053
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9793-9273
0000-0003-2037-9575
0000-0003-2200-7505
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers15082271
PMID 37190199
PQID 2806506879
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10136643
proquest_miscellaneous_2814527491
proquest_journals_2806506879
gale_infotracmisc_A747308980
gale_infotracacademiconefile_A747308980
pubmed_primary_37190199
crossref_citationtrail_10_3390_cancers15082271
crossref_primary_10_3390_cancers15082271
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230413
PublicationDateYYYYMMDD 2023-04-13
PublicationDate_xml – month: 4
  year: 2023
  text: 20230413
  day: 13
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Golani (ref_29) 2015; 125
Pan (ref_18) 2008; 40
Karni (ref_24) 2007; 14
Zhang (ref_23) 2021; 6
Wang (ref_31) 2020; 3
Apte (ref_42) 2019; 176
Dvinge (ref_19) 2018; 592
Duan (ref_51) 2015; 112
Malvi (ref_32) 2020; 9
Szklarczyk (ref_36) 2021; 49
Nowakowski (ref_49) 2018; 21
ref_55
Yussof (ref_1) 2022; 62
Lago (ref_47) 2021; 12
Chen (ref_34) 2021; 14
Rahem (ref_46) 2020; 61
Miura (ref_56) 2012; 33
Zhu (ref_9) 2018; 9
Chao (ref_20) 2021; 11
ref_16
ref_15
Moroney (ref_50) 2020; 11
Wang (ref_17) 2008; 456
Aubol (ref_28) 2016; 63
Prinos (ref_54) 2011; 18
Yang (ref_52) 2016; 164
ref_61
Yang (ref_27) 2018; 1865
Peng (ref_44) 2017; 16
Muraki (ref_35) 2004; 279
Hatcher (ref_37) 2018; 25
Zhang (ref_53) 2013; 3
Damen (ref_59) 2021; 288
Chen (ref_63) 2018; 9
Jia (ref_26) 2019; 25
Sette (ref_11) 2013; 2013
Barrera (ref_48) 2016; 5
Piva (ref_6) 2014; 6
ref_62
Luo (ref_25) 2017; 77
Tsoi (ref_14) 2021; 11
Gehring (ref_33) 2021; 37
Gong (ref_13) 2018; 24
Shepard (ref_21) 2009; 10
Williams (ref_38) 2014; 9
Jeselsohn (ref_5) 2017; 114
Davies (ref_2) 2011; 378
Mansouri (ref_4) 2018; 18
Yao (ref_10) 2020; 11
Wu (ref_39) 2018; 78
Koedoot (ref_58) 2019; 10
Varlakhanova (ref_60) 2011; 332
ref_30
Yu (ref_7) 2020; 11
Heckler (ref_43) 2014; 281
Dong (ref_41) 2021; 12
Cerasuolo (ref_22) 2020; 8
Ring (ref_3) 2004; 11
Zhang (ref_45) 2018; 37
Gao (ref_57) 2021; 12
ref_40
ref_8
Zhang (ref_12) 2013; 73
References_xml – volume: 281
  start-page: 2431
  year: 2014
  ident: ref_43
  article-title: ERK/MAPK regulates ERR gamma expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER plus breast cancer
  publication-title: FEBS J.
  doi: 10.1111/febs.12797
– volume: 279
  start-page: 24246
  year: 2004
  ident: ref_35
  article-title: Manipulation of alternative splicing by a newly developed inhibitor of Clks
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M314298200
– volume: 11
  start-page: 5435
  year: 2020
  ident: ref_50
  article-title: Integrative transcriptome and chromatin landscape analysis reveals distinct epigenetic regulations in human memory B cells
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19242-6
– volume: 5
  start-page: e11752
  year: 2016
  ident: ref_48
  article-title: A new view of transcriptome complexity and regulation through the lens of local splicing variations
  publication-title: Elife
  doi: 10.7554/eLife.11752
– volume: 11
  start-page: 592912
  year: 2020
  ident: ref_10
  article-title: Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.592912
– volume: 14
  start-page: 185
  year: 2007
  ident: ref_24
  article-title: The gene encoding the splicing factor SF2/ASF is a proto-oncogene
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb1209
– volume: 73
  start-page: 246
  year: 2013
  ident: ref_12
  article-title: SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of NCOR2/SMRT That Is Associated with Tamoxifen Resistance and Control of ER alpha Transcriptional Activity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-2241
– volume: 288
  start-page: 6286
  year: 2021
  ident: ref_59
  article-title: Targeting dormant tumor cells to prevent cancer recurrence
  publication-title: FEBS J.
  doi: 10.1111/febs.15626
– volume: 18
  start-page: 673
  year: 2011
  ident: ref_54
  article-title: Alternative splicing of SYK regulates mitosis and cell survival
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb.2040
– volume: 12
  start-page: 3332
  year: 2021
  ident: ref_57
  article-title: A deep learning approach to identify gene targets of a therapeutic for human splicing disorders
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-23663-2
– volume: 12
  start-page: 628690
  year: 2021
  ident: ref_41
  article-title: Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.628690
– volume: 61
  start-page: 103047
  year: 2020
  ident: ref_46
  article-title: Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
  publication-title: Ebiomedicine
  doi: 10.1016/j.ebiom.2020.103047
– volume: 63
  start-page: 218
  year: 2016
  ident: ref_28
  article-title: Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2016.05.034
– volume: 37
  start-page: 355
  year: 2021
  ident: ref_33
  article-title: Anything but Ordinary—Emerging Splicing Mechanisms in Eukaryotic Gene Regulation
  publication-title: Trends Genet.
  doi: 10.1016/j.tig.2020.10.008
– volume: 9
  start-page: 297
  year: 2014
  ident: ref_38
  article-title: High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines
  publication-title: Epigenetics
  doi: 10.4161/epi.27111
– volume: 9
  start-page: 1595
  year: 2018
  ident: ref_9
  article-title: Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-03951-0
– volume: 10
  start-page: 242
  year: 2009
  ident: ref_21
  article-title: The SR protein family
  publication-title: Genome Biol.
  doi: 10.1186/gb-2009-10-10-242
– volume: 14
  start-page: 60
  year: 2021
  ident: ref_34
  article-title: CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-021-01072-8
– volume: 11
  start-page: e554
  year: 2021
  ident: ref_14
  article-title: KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer
  publication-title: Clin. Transl. Med.
  doi: 10.1002/ctm2.554
– volume: 114
  start-page: E4482
  year: 2017
  ident: ref_5
  article-title: Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1620993114
– volume: 125
  start-page: 1648
  year: 2015
  ident: ref_29
  article-title: Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI74440
– volume: 11
  start-page: 550469
  year: 2020
  ident: ref_7
  article-title: PKM2-c-Myc-Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.550469
– volume: 24
  start-page: 3681
  year: 2018
  ident: ref_13
  article-title: BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-2259
– volume: 378
  start-page: 771
  year: 2011
  ident: ref_2
  article-title: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60993-8
– ident: ref_15
  doi: 10.3390/life12010093
– volume: 3
  start-page: 268
  year: 2020
  ident: ref_31
  article-title: SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-020-0983-4
– volume: 8
  start-page: 474
  year: 2020
  ident: ref_22
  article-title: The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.00474
– ident: ref_55
  doi: 10.3390/ijms19010075
– volume: 25
  start-page: 630
  year: 2019
  ident: ref_26
  article-title: Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation
  publication-title: RNA
  doi: 10.1261/rna.068619.118
– volume: 37
  start-page: 1869
  year: 2018
  ident: ref_45
  article-title: IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-017-0027-9
– volume: 6
  start-page: 66
  year: 2014
  ident: ref_6
  article-title: Sox2 promotes tamoxifen resistance in breast cancer cells
  publication-title: EMBO Mol. Med.
  doi: 10.1002/emmm.201303411
– volume: 18
  start-page: 668
  year: 2018
  ident: ref_4
  article-title: Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required
  publication-title: Curr. Cancer Drug Targets
  doi: 10.2174/1568009617666170808110820
– volume: 12
  start-page: 3885
  year: 2021
  ident: ref_47
  article-title: Promoter G-quadruplexes and transcription factors cooperate to shape the cell type-specific transcriptome
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-24198-2
– volume: 25
  start-page: 460
  year: 2018
  ident: ref_37
  article-title: SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
  publication-title: Cell Chem. Biol.
  doi: 10.1016/j.chembiol.2018.01.013
– volume: 49
  start-page: D605
  year: 2021
  ident: ref_36
  article-title: The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa1074
– volume: 16
  start-page: 161
  year: 2017
  ident: ref_44
  article-title: Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-017-0727-3
– volume: 164
  start-page: 805
  year: 2016
  ident: ref_52
  article-title: Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing
  publication-title: Cell
  doi: 10.1016/j.cell.2016.01.029
– volume: 592
  start-page: 2987
  year: 2018
  ident: ref_19
  article-title: Regulation of alternative mRNA splicing: Old players and new perspectives
  publication-title: FEBS Lett.
  doi: 10.1002/1873-3468.13119
– ident: ref_40
  doi: 10.3390/cancers13153688
– volume: 77
  start-page: 1168
  year: 2017
  ident: ref_25
  article-title: SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-1919
– volume: 9
  start-page: 2464
  year: 2018
  ident: ref_63
  article-title: Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-04815-3
– volume: 9
  start-page: 77
  year: 2020
  ident: ref_32
  article-title: LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
  publication-title: Oncogenesis
  doi: 10.1038/s41389-020-00263-1
– volume: 62
  start-page: 22
  year: 2022
  ident: ref_1
  article-title: Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review
  publication-title: Breast
  doi: 10.1016/j.breast.2022.01.012
– volume: 456
  start-page: 470
  year: 2008
  ident: ref_17
  article-title: Alternative isoform regulation in human tissue transcriptomes
  publication-title: Nature
  doi: 10.1038/nature07509
– volume: 21
  start-page: 1784
  year: 2018
  ident: ref_49
  article-title: Regulation of cell-type-specific transcriptomes by microRNA networks during human brain development
  publication-title: Nat. Neurosci.
  doi: 10.1038/s41593-018-0265-3
– volume: 176
  start-page: 1248
  year: 2019
  ident: ref_42
  article-title: VEGF in Signaling and Disease: Beyond Discovery and Development
  publication-title: Cell
  doi: 10.1016/j.cell.2019.01.021
– volume: 10
  start-page: 6021
  year: 2019
  ident: ref_58
  article-title: Splicing regulatory factors in breast cancer hallmarks and disease progression
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27215
– ident: ref_8
  doi: 10.1186/s12885-016-2490-z
– volume: 33
  start-page: 2311
  year: 2012
  ident: ref_56
  article-title: Splice isoforms as therapeutic targets for colorectal cancer
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgs347
– volume: 112
  start-page: 13360
  year: 2015
  ident: ref_51
  article-title: Transcriptome analyses reveal molecular mechanisms underlying functional recovery after spinal cord injury
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1510176112
– volume: 11
  start-page: 66
  year: 2021
  ident: ref_20
  article-title: Regulatory roles and mechanisms of alternative RNA splicing in adipogenesis and human metabolic health
  publication-title: Cell Biosci.
  doi: 10.1186/s13578-021-00581-w
– volume: 3
  start-page: 1228
  year: 2013
  ident: ref_53
  article-title: Misregulation of Pre-mRNA Alternative Splicing in Cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-13-0253
– ident: ref_16
  doi: 10.3390/cancers13071511
– ident: ref_30
  doi: 10.3390/cells9010019
– ident: ref_61
  doi: 10.3390/cancers12030533
– volume: 40
  start-page: 1413
  year: 2008
  ident: ref_18
  article-title: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing
  publication-title: Nat. Genet.
  doi: 10.1038/ng.259
– volume: 332
  start-page: 180
  year: 2011
  ident: ref_60
  article-title: Regulation of SMRT corepressor dimerization and composition by MAP kinase phosphorylation
  publication-title: Mol. Cell. Endocrinol.
  doi: 10.1016/j.mce.2010.10.010
– volume: 6
  start-page: 78
  year: 2021
  ident: ref_23
  article-title: Alternative splicing and cancer: A systematic review
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00486-7
– volume: 78
  start-page: 671
  year: 2018
  ident: ref_39
  article-title: Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER alpha-GREB1 Transcriptional Axis
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1327
– volume: 11
  start-page: 643
  year: 2004
  ident: ref_3
  article-title: Mechanisms of tamoxifen resistance
  publication-title: Endocr. Relat. Cancer
  doi: 10.1677/erc.1.00776
– volume: 2013
  start-page: 421606
  year: 2013
  ident: ref_11
  article-title: Alternative splicing: Role in cancer development and progression
  publication-title: Int. J. Cell Biol.
– volume: 1865
  start-page: 1161
  year: 2018
  ident: ref_27
  article-title: SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma
  publication-title: Biochim. Biophys. Acta Mol. Cell Res.
  doi: 10.1016/j.bbamcr.2018.05.017
– ident: ref_62
  doi: 10.3390/ijms232012290
SSID ssj0000331767
Score 2.3133535
Snippet About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for...
Overexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11. SRSF5 is found...
Simple SummaryOverexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11....
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2271
SubjectTerms Alternative splicing
Breast cancer
Cancer therapies
Cell cycle
Dosage and administration
Drug resistance
Drug therapy
Endocrine therapy
Estrogen receptors
Gene expression
Genetic aspects
Genetic regulation
Health aspects
Kinases
Metastases
Metastasis
mRNA
Phosphorylation
Plasmids
Proteins
Tamoxifen
SummonAdditionalLinks – databaseName: ProQuest Central (New)
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9wwDI8YSNNepo19cBtDmTSJvRTSJk3TJ8ShO6FJh-C4SbxVaZqIQ1vLaJn487HbXKFI8Bzn5Itj--fYtQn5YRz47EKLwMXa4ggzEyirWMCM1ZY5qfK22fPsRB7_Fr8u4gv_4Fb7ssqVTWwNdVEZfCPfbzOATKokPbj-F-DUKMyu-hEar8gGmGAFwdfGeHJyOu9fWRgH_yiTrqcPh_h-3-Bh3tTYBj2KknDgjp4a5UdeaVgx-cgFTd-Rtx470sNO2O_Jmi03yeuZz45_IFfn8_NpTOfdeHlbUwB3dHLnS11LWjk6PuMRl1zuhbSp6KwqWkq60H-ru6WzJWyuEVEC93RZ0sk8OG2ruv5bOsby9YYetf_sI1lMJ4uj48DPUgiMUGkTCMulcGmewnmAeKxLQm0SZmXhoihXJjLMCW1zUN_UFHBmXDhjuSoUxMigqJ_IelmVdovQIjKAAcFExlpA8KlVDiAgNIVkwgI4yUdkb3WimfF9xnHcxZ8M4g0UQfZEBCPys99w3bXYeJ50F0WUofLBbxrtvyEAzrCNVXYIwRFnKlVsRLYHlKA0Zri8EnLmlbbOHq7YiHzvl3EnFqKVtrpFmlDEEMmnwMvn7k70TPME0VUKu9XgtvQE2Mp7uFIuL9uW3iG2zgNw-OVlvr6SNzjuHrNZId8m683Nrf0GoKjJd_zNvwet_gxr
  priority: 102
  providerName: ProQuest
Title SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/37190199
https://www.proquest.com/docview/2806506879
https://www.proquest.com/docview/2814527491
https://pubmed.ncbi.nlm.nih.gov/PMC10136643
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBdbC2Mvo91ntjZoMNhenMmSLMsPYzQlWRmkdGkKeTOyLNGMzt4St2T__e5sJ6tLB3vWSZbvQ_c7dLoj5J314LNzIwMfGYctzGygnWYBs8445pXO6mLPk1N1ciG_zqP533ZALQNX94Z22E_qYnk1WP_6_RkM_hNGnBCyf7TIn-UKK5tzju_Jd8EtxWilkxbr18eyAFdZd5TlLOaBUolsSv3ct0bHS909q285q24i5S3PNN4jT1pISY8aHdgnD1zxlDyatJfmz8j38-n5OKLTpuu8W1HAfHS0bjNgC1p6OvwmuFBCDUJalXRS5jUlnZkf5XrhXQGTVwg0Yfd0UdDRNDirk71uHB1iVntFj-s_e05m49Hs-CRoWywEVuqkCqQTSvokS4A3IDXn49DYmDmVe84zbbllXhqXgVUnNgf-CemtEzrXEDqD_b4gO0VZuFeE5twCNISTMzISYlKjMxBCaHPFpAPMkvXIYMPR1Lblx7ELxlUKYQiKIL0jgh75sJ3ws6m88W_S9yiiFLUE1rSmfVoAO8PqVukRxEyC6USzHjnoUIIt2e7wRsjpRhXT-u6ZKR0nPfJ2O4wzMT-tcOU10oQyggA_gb28bHRiu2kRI-hKYLbuaMuWACt8d0eKxWVd6TvEinqAGV__x4ffkMccABjedIXigOxUy2t3CICpyvpkdzg6PZv2ycMv87Bfm8UfNn0VQw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqrQRcEO8uFDASCC5pHdtJnANC3bKrLe2uynaReosSxxZblaQ0KZQfxX9kJi-aSnDr2eNoknl9E49nCHmtLcTsNJaO9WKDI8y0o4xiDtMmNsz6KqmaPc_m_vSL_HTsHa-R3-1dGCyrbH1i5ajTXOM_8u3qBJD5Kgg_nH13cGoUnq62IzRqtdg3v35Cyla83_sI8n3D-WS83J06zVQBR0sVlo40wpc2TEKInMCosYEb64AZP7WcJ0pzzayMTQKKHOrUBfuTVhuhUgXZIsMhEeDx16WATGZA1kfj-eGi-6nDBDzUD-oWQkKEbFuj7M4L7LrOeeD2ot_1GHAlCPYLNK9EvMk9creBqnSn1q37ZM1kD8itWXMY_5CcHC2OJh5d1NPsTUEBS9LxZVNZm9Hc0tFnwYUv_C2Xljmd5WlFSZfxt_xyZU0GmwsEsMA9XWV0vHAOqyKyH4aOsFq-pLvVmz0iy5v4yI_JIMszs0FoyjVATvDIXiwh141VApjD1anPpAEslAzJVvtFI920NcfpGqcRpDcoguiaCIbkXbfhrO7o8W_StyiiCG0dnqnj5soCcIZds6IdyMUEU6FiQ7LZowQb1f3lVshR4yOK6K9GD8mrbhl3Yt1bZvILpHGlxwMZAi9Pap3omBYBgrkQdquetnQE2Dm8v5KtvlYdxF3s1AdY9On_-XpJbk-Xs4PoYG--_4zc4YDv8CDNFZtkUJ5fmOeAx8rkRWMFlEQ3bHd_AIMhSOA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqrVRxQbxZKGAkEFzSdWwncQ4IddtdtZRdLdtF6i1KHFtdBElpUig_jX_HTF40leDWs8fRJPP6Jh7PEPJKW4jZaSwd68UGR5hpRxnFHKZNbJj1VVI1e57N_YPP8sOJd7JBfrd3YbCssvWJlaNOc43_yEfVCSDzVRCObFMWsdifvj_77uAEKTxpbcdp1CpyZH79hPSteHe4D7J-zfl0sto7cJoJA46WKiwdaYQvbZiEEEWBaWMDN9YBM35qOU-U5ppZGZsElDrUqQu2KK02QqUKMkeGAyPA-28GkBSxAdkcT-aLZfeDhwl4qB_U7YSECNlIoxzPC-zAznng9iLh9XhwJSD2izWvRL_pHXK7ga10t9azu2TDZPfI1qw5mL9Pvhwvj6ceXdaT7U1BAVfSyWVTZZvR3NLxJ8GFL_wdl5Y5neVpRUlX8bf8cm1NBpsLBLPAPV1ndLJ0FlVB2Q9Dx1g5X9K96s0ekNVNfOSHZJDlmXlMaMo1wE_wzl4sIe-NVQL4w9Wpz6QBXJQMyU77RSPdtDjHSRtfI0h1UATRNREMydtuw1nd3ePfpG9QRBHaPTxTx831BeAMO2hFu5CXCaZCxYZku0cJ9qr7y62Qo8ZfFNFf7R6Sl90y7sQauMzkF0jjSo8HMgReHtU60TEtAgR2IexWPW3pCLCLeH8lW59W3cRd7NoHuPTJ__l6QbbA3qKPh_Ojp-QWB6iHZ2qu2CaD8vzCPANoVibPGyOgJLphs_sDw_JNFQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SRSF5+Regulates+the+Expression+of+BQ323636.1+to+Modulate+Tamoxifen+Resistance+in+ER-Positive+Breast+Cancer&rft.jtitle=Cancers&rft.au=Tsoi%2C+Ho&rft.au=Fung%2C+Nicholas+Nok-Ching&rft.au=Man%2C+Ellen+P+S&rft.au=Leung%2C+Man-Hong&rft.date=2023-04-13&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=8&rft_id=info:doi/10.3390%2Fcancers15082271&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon